We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
58.00 | 3.20% | 1,871.00 | 1,870.00 | 1,873.00 | 1,871.00 | 1,750.00 | 1,750.00 | 171,703 | 13:02:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 21.35 | 4.1B |
TIDMHIK
RNS Number : 4938W
Hikma Pharmaceuticals Plc
23 April 2021
Hikma Pharmaceuticals PLC
Voting Results of 2021 Annual General Meeting
LONDON, 23 April 2021 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting ("AGM"), held at 1 New Burlington Place, W1S 2HR, London on 23 April 2021 commenced at 1:00 pm. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 15 and 17 were passed as ordinary resolutions and Resolutions 16 and 18 to 22 were passed as special resolutions.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the to the FCA's Electronic Submission System and will be available from the National Storage Mechanism.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 24 February 2021) is set out below. The number of Ordinary Shares in issue on 23 April 2021 was 243,604,637. There were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 230,771,404.
Resolution Votes For % Votes Against % Total Cast Withheld 1. To receive the 2020 report and accounts 176,723,133 100.0 16,692 0 176,739,825 1,537,096 ------------ ------ -------------- ----- ------------ ---------- 2. To approve a final dividend of 34 cents per share 178,275,824 100.0 152 0 178,275,976 945 ------------ ------ -------------- ----- ------------ ---------- 3. To re-appoint PricewaterhouseCoopers LLP as auditors 177,053,202 99.3 1,222,474 0.7 178,275,676 1,245 ------------ ------ -------------- ----- ------------ ---------- 4. To authorise the Audit Committee to determine the auditors' remuneration 178,174,755 99.9 100,365 0.1 178,275,120 1,801 ------------ ------ -------------- ----- ------------ ---------- 5. To elect Douglas Hurt as a director 174,859,594 98.1 3,414,131 1.9 178,273,725 3,196 ------------ ------ -------------- ----- ------------ ---------- 6. To re-elect Said Darwazah as a director 171,553,543 97.2 4,923,908 2.8 176,477,451 1,799,470 ------------ ------ -------------- ----- ------------ ---------- 7. To re-elect Siggi Olafsson as a director 176,112,071 98.8 2,163,336 1.2 178,275,407 1,514 ------------ ------ -------------- ----- ------------ ---------- 8. To re-elect Mazen Darwazah as a director 171,246,066 96.1 6,949,669 3.9 178,195,735 81,186 ------------ ------ -------------- ----- ------------ ---------- 9. To re-elect Patrick Butler as a director 172,831,258 97.0 5,434,621 3.1 178,265,879 11,041 ------------ ------ -------------- ----- ------------ ---------- 10. To re-elect Ali Al-Husry as a director 175,142,703 98.3 3,053,032 1.7 178,195,735 81,186 ------------ ------ -------------- ----- ------------ ---------- 11. To re-elect Dr. Pamela Kirby as a director 167,790,753 95.1 8,655,778 4.9 176,446,531 1,830,390 ------------ ------ -------------- ----- ------------ ---------- 12. To re-elect John Castellani as a director 175,101,327 98.9 1,975,760 1.1 177,077,087 1,199,834 ------------ ------ -------------- ----- ------------ ---------- 13 . To re-elect Nina Henderson as a director 175,403,863 98.4 2,871,070 1.6 178,274,933 1,988 ------------ ------ -------------- ----- ------------ ---------- 14 . To re-elect Cynthia Schwalm as a director 154,099,252 86.5 24,120,681 13.5 178,219,933 56,988 ------------ ------ -------------- ----- ------------ ---------- 15. To approve the remuneration report for the year ended 31 December 2020 160,014,990 90.4 17,063,364 9.6 177,078,354 1,198,566 ------------ ------ -------------- ----- ------------ ---------- 16. To approve the adoption of the new articles of association for the Company 177,680,870 99.7 593,294 0.3 178,274,164 2,757 ------------ ------ -------------- ----- ------------ ---------- 17. Authority to allot shares 154,848,864 86.9 23,426,822 13.1 178,275,686 1,235 ------------ ------ -------------- ----- ------------ ---------- 18 . To dis-apply pre-emption rights for general purposes 177,563,944 99.6 711,824 0.4 178,275,768 1,153 ------------ ------ -------------- ----- ------------ ---------- 19. To dis-apply pre-emption rights for an acquisition or other capital investment 174,606,709 97.9 3,668,585 2.1 178,275,294 1,627 ------------ ------ -------------- ----- ------------ ---------- 20. To authorise the Company to purchase its own shares 176,712,127 99.2 1,480,842 0.8 178,192,969 83,952 ------------ ------ -------------- ----- ------------ ---------- 21. To authorise the Company to hold general meetings on no less than 14 clear days' notice 169,544,820 95.1 8,731,027 4.9 178,275,847 1,074 ------------ ------ -------------- ----- ------------ ----------
Declaration of final dividend
The dividend of 34 cents per share will be paid on 26 April 2021 to shareholders on the register on 19 March 2021. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.3762998 to GBP1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.709JD.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC Peter Speirs Company Secretary +44 20 7399 2670 Susan Ringdal EVP, Strategic Planning and Global Affairs +44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGSEUFLDEFSEDL
(END) Dow Jones Newswires
April 23, 2021 10:51 ET (14:51 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions